Large B‐cell lymphoma with Hodgkin's features

Garcı́a, Juan F.; Mollejo, Manuela; Fraga, Máximo; Forteza, Jerónimo; Muniesa, J A; Pérez‐Guillermo, Miguel; Pérez-Seoane, C; Rivera, Teresa; Ortega, Pablo; Piris, Miguel Á.

doi:10.1111/j.1365-2559.2005.02175.x

Cited by 91 publications

(64 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…98 Tumors with transitional or intermediate morphologic and phenotypic features between these 2 entities were described (Figure 3). 95,99 These observations suggested that a true biologic gray zone between these 2 entities could exist, a finding supported by profiling at the epigenetic level. 100 The 2008 WHO classification incorporates these new ideas and recognizes a provisional category of B-cell neoplasms with features intermediate between DLBCL and CHL.…”

Section: Gray Zones Between Hodgkin Lymphoma and Primary Mediastinal mentioning

confidence: 92%

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Campo

Swerdlow

Harris

et al. 2011

Blood

1,721

1,414

View full text Add to dashboard Cite

The World Health Organization classification of lymphoid neoplasms updated in 2008 represents a worldwide consensus on the diagnosis of these tumors and is based on the recognition of distinct diseases, using a multidisciplinary approach. The updated classification refined the definitions of well-recognized diseases, identified new entities and variants, and incorporated emerging concepts in the understanding of lymphoid neoplasms. However, some questions were unresolved, such as the extent to which specific genetic or molecular alterations define certain tumors, and the status of provisional entities, categories for which the World Health Organization working groups felt there was insufficient evidence to recognize as distinct diseases at this time. In addition, since its publication, new findings and ideas have been generated. This review summarizes the scientific rationale for the classification, emphasizing changes that have had an effect on practice guidelines. The authors address the criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly. The issue of borderline categories having overlapping features with large B-cell lymphomas, as well as several provisional entities, is reviewed. These new observations chart a course for future research in the field. (Blood. 2011

show abstract

Section: Gray Zones Between Hodgkin Lymphoma and Primary Mediastinal mentioning

confidence: 92%

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Campo

Swerdlow

Harris

et al. 2011

Blood

1,721

1,414

View full text Add to dashboard Cite

show abstract

“…Xiao et al (2004) detected nuclear REL staining in a high percentage (B85%) of Reed-Sternberg cells of classic HL. Nuclear REL staining has also been seen in the majority of 9 cases of Hodgkin's-like large cell lymphoma (Garcia et al, 2005), and in 5 of 6 and 7/7 cases of mediastinal large B-cell lymphoma (Savage et al, 2003;Feuerhake et al, 2005). Moreover, Rodig et al (2005) have recently presented data suggesting that nuclear REL staining and high level of expression of adaptor protein TRAF1, a possible REL target gene product, can be used to distinguish classical HL cells from other types of B-cell lymphomas, such as anaplastic large cell lymphoma, lymphocyte predominant HL, and nonmediastinal DLBCL.…”

Section: Multiple Familial Trichoepitheliomamentioning

confidence: 99%

Mutations in the NF-κB signaling pathway: implications for human disease

2006

View full text Add to dashboard Cite

“…[2][3][4][5] Although more recent publications defined a particular methylation profile for this entity, 6,7 and a particular immunohistochemistry scoring system to distinguish it from CHL and PMBCL, 8 there is a need for clarification of the clinico-pathological diagnostic criteria for MGZL. Previous retrospective studies 4,5,[9][10][11][12] (including from 2 to 112 cases) showed that patients with an MGZL had a poorer outcome than patients with a PMBCL or diffuse large B-cell lymphoma (DLBCL). The poor prognosis was confirmed by the prospective study of the National Cancer Institute that included 24 MGZL cases treated with rituximab and an intensified chemotherapy regimen (namely DA-EPOCH-R: dose adapted etoposide, prednisolone, oncovin, cyclophosphamide, doxorubicin) with a shorter progression-free survival (PFS) and overall survival (OS) as compared with PMBCL.…”

Section: Introductionmentioning

confidence: 99%

Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association

et al. 2016

View full text Add to dashboard Cite

Mediastinal gray zone lymphoma, B-cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma, have not been well described in the literature. We report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis. Cases were defined as classical Hodgkin lymphoma-like morphology (64.6%) with primary mediastinal B-cell lymphoma immunophenotype, primary mediastinal B-cell lymphoma-like morphology (30.3%) with classical Hodgkin lymphoma or composite (5.1%) (synchronous occurrence of classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma). The median age was 32 years (13-83 years); 55% were women. Thirteen of 81 evaluable cases (16%) were Epstein-Barr virus-positive. Twenty-eight percent of patients presented primary refractory disease (progression under first-line treatment or relapse within one year). The 3-year event-free and overall survival rates were 63% and 80%, respectively. Patients treated with a standard regimen (RCHOP/ABVD) had worse event-free survival (P=0.003) and overall survival (P=0.02) than those treated with a dose-intensive chemotherapy (high-dose RCHOP/escalated BEACOPP). Rituximab added to chemotherapy was not associated with better event-free survival (P=0.55) or overall survival (P=0.88). Radiotherapy for patients in complete remission had no impact on eventfree survival. In multivariate prognostic analysis, ECOG-PS and anemia were the strongest factors associated with a shorter event-free survival and overall survival, respectively. In conclusion, this report describes the largest series of mediastinal gray zone lymphoma. Our data suggest that a dose-intensive treatment might improve the outcome of this rare and aggressive disease.

show abstract

Large B‐cell lymphoma with Hodgkin's features

Abstract: These findings suggest that DLBCLs with HL features constitute a distinctive subgroup of aggressive lymphomas whose neoplastic growth and peculiar characteristics could be facilitated by a particular microenvironment found in the mediastinum.

Cited by 91 publications

References 29 publications

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Mutations in the NF-κB signaling pathway: implications for human disease

Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association

Contact Info

Product

Resources

About